GlassScriptPhysician profile
Barry A Effron
NPI 1376569640
$4,411.30
in general payments reported to CMS, 2019-2025
26 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $346 · 2021: $95.99 · 2022: $546 · 2023: $594 · 2024: $817 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $866.03 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $520.14 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $477.76 | 2019-2024 | Repatha |
| Pfizer INC. | $429.45 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $404.38 | 2019-2024 | |
| Abbott Laboratories | $209.22 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $168.76 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.55 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $143.42 | 2019-2021 | |
| Novo Nordisk INC | $142.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $136.67 | 2019-2020 | |
| Edwards Lifesciences Corporation | $123.14 | 2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $108.72 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $100.78 | 2019-2024 | |
| Boston Scientific Corporation | $93.37 | 2022-2024 | Watchman Access System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $52.14 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $50.91 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $44.32 | 2023-2024 | Onpattro |
| Irhythm Technologies, INC. | $37.49 | 2023 | Zio Xt Patch |
| Atricure, INC. | $34.91 | 2023 | |
| Impulse Dynamics (USA) INC. | $31.06 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.47 | 2022 | |
| Astellas Pharma US INC | $19.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.53 | 2024 | Opsumit |
| Lundbeck LLC | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Effron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.